Ziping Wei, BlissBio CEO
May 8, 2023 10:59 AM EDT
Deals
China
Pharma

Ei­sai’s can­cer drug Halaven at the cen­ter of $2B pact with Bliss­Bio, like its Bris­tol My­ers ADC deal

Kyle LaHucik

Senior Reporter

Ei­sai plans to pay up to $2 bil­lion to de­vel­op an an­ti­body-drug con­ju­gate with Chi­nese biotech Bliss Bio­phar­ma­ceu­ti­cal, and the Japan­ese …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times